Bile Duct StoneNCIt concept

https://minerva-ebp.be/FR/Article/2380
2024
France
critical appraisal or critical reading
Caffeine Not Routinely Consumed
Treatment Epoch
Negation
Multiple Known Primary Tumors Absent at Initial Melanoma Diagnosis
Patient was not Postmenopausal with no Prior Oophorectomy
No Treatment for Diabetes
EWS Off Protocol Therapy/Study Table
No History of Neonatal Complication
Targeted Molecular Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
On Treatment
Cancer History Absent
Medication Not Taken
Case
Fluorescence In Situ Hybridization Was Not Performed
Therapy Object
Stayed the Same
Treatment Study
Not Lost to Follow-Up
Breast Cancer Anti-Estrogen Resistance Protein 1
Chemotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
Lymph Node Dissection Was Not Performed
Tumor Reoccurrence Absent After Initial Treatment
Adjuvant Post-operative Pharmaceutical Therapy Was Not Administered
AML Off Protocol Therapy/Study Table
Radiation History Negative
Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Not Performed
symptom, nos
ROS1 Rearrangement Analysis Was Not Performed
First Degree Family History Thyroid Cancer Negative
Interferon Gamma Treatment was not Administered 90 Days Prior to Specimen Resection
IV Anesthesia was not Administered
New Disease is not Multifocal
Has No Sibling
Preservation
ALK Rearrangement Analysis Was Not Performed
Nitric Oxide
ATRX Gene Mutation Negative
Subsequent Known Primary Melanoma(s) Not Found During the Follow-Up
Use of Smokeless Tobacco at Time of Diagnosis Negative
Conservation
No History of Myopathy
No Cases Transmission Pattern
EGFR Mutation Analysis Was Not Performed
Paraneoplastic Syndrome is Not Present
Complication
gallstones
No History of Rheumatic Fever
MGMT Promoter Methylation Testing Was Not Performed
Adjuvant Post-operative Targeted Molecular Therapy Was Not Administered
No History of Gestational Complication
Any Metastatic Diagnosis Absent
Immunotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
No Known History of Illicit Drug Use
Symptomatic Presentation
Treat
Routine Cytogenetics Were not Completed
Additional Surgery for New Metastatic Tumor Event Was Not Performed
Bile Duct Stone
BRAF Mutation Analysis Was Not Performed
Symptomatic Therapy
EGFR Amplification Analysis Was Not Performed
During Treatment
Unemployed
No History of Kawasaki Disease
First Degree Family History of Primary Brain Tumor Negative
Nitric Oxide Measurement
Preoperative IV Antacids were not Administered
snacks
Additional Molecular Studies Were Not Performed
Regular Smokeless Tobacco Use for Six Weeks or More Negative
No History of Other Muscular Dystrophy or Glycogen Storage Disorder
CTNND1 wt Allele
Neither Case or Control Status
Preservation Procedure
Another Form of Birth Control was not Used
Interferon Gamma Treatment was not Administered Prior to Specimen Resection
EGFR Gene Amplification Negative
BCAR1 wt Allele
RET Rearrangement Analysis Was Not Performed
complication, nos
Preoperative IV Sedation was Not Administered
Documentation Absent
Preoperative IV Opiates were not Administered
History of Medical Treatment Absent
No Known History of Alcohol Use
Adjuvant Post-operative Chemotherapy Was Not Administered
Other Preoperative IV Medications were not Administered
Norway
GDC Treatment Frequency Terminology
Chemical/Occupational Exposure Absent
Hypertension Absent
KRAS Mutation Analysis Was Not Performed
Can
Additional Surgery for New Tumor Event Absent
NON Mouse
Minor Criteria for Rheumatic Heart Disease Not Present
Evidence of Disease Absent after Completion of Therapy
Complicating
Conservative Treatment
NRAS Mutation Analysis Was Not Performed
Patient was Not Previously Evaluated for Current Chief Complaint
NF1 Mutation Analysis Was Not Performed
No History of Non-Cardiac Surgery
Peripheral Blood Immunophenotyping and Cytochemistry Were Not Performed
ATRX Mutation Analysis Was Not Performed
PTEN Mutation Analysis Was Not Performed
Therapeutic Ionizing Radiation to Head History Absent
Preoperative IV Antiemetics were not Administered
Family History of Stomach Cancer Absent
Radiation Therapy Not Received
10q23/PTEN Locus Deletion Analysis Was Not Performed
KIT Mutation Analysis Was Not Performed
New Tumor Event After Initial Treatment Absent
biliary calculus, nos
No Response to Intervention for Kawasaki Disease
Tumor Progression Absent After Initial Treatment
Additional Immunohistochemistry Was Not Performed
Biomaterial Treatment
History of Colorectal Cancer Negative
Options
TP53 Mutation Analysis Was Not Performed
Cholelithiasis
Adjuvant Post-operative Immunological Therapy Was Not Administered
BRAF Rearrangement Analysis Was Not Performed
No History of Congenital Heart Disease
MET Mutation Analysis Was Not Performed
True Case Status
Chemotherapy Not Received
Case Dosing Unit
Hormone Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
Catenin Delta-1
Neither
Adjuvant I-131 Therapy Negative
PDGFRA Mutation Analysis Was Not Performed
Local Anesthesia Agents were not Administered
ERBB2 Mutation Analysis Was Not Performed
SDH Complex Mutation Analysis Was Not Performed
IDH Family Mutation Analysis Was Not Performed
Regional Anesthesia was not Administered
Chief Complaint was Not Witnessed
Treatment
IDH Family Wildtype
First Degree Family History Cancer Negative
Chief Complaint Not Caused by Trauma
Adjuvant Post-operative Radiation Therapy Was Not Administered
Optional
Intercurrent Illness is Absent at Onset of Chief Complaint
Physician Diagnosed Diabetes Absent
1p/19q Deletion Analysis Was Not Performed
Radiation Was Not Administered as an Additional Treatment for a New Tumor Event
Intervention Not Given for Kawasaki Disease
Coronavirus Anxiety Scale
Additional Surgery for New Loco-Regional Tumor Event Was Not Performed
PTEN Gene Mutation Negative
Packaging Case

---
https://www.cochrane.org/fr/CD012608/LIVER_la-modification-de-lapport-en-graisses-alimentaires-est-elle-benefique-ou-risquee-pour-les-personnes
2024
United Kingdom
review of literature
french abstract
Dietary Route of Administration
gallstones
Modification
Alteration
Cholelithiasis
dietary fats
What Month is it
risk
Amendment
grease, nos
Amendment Regulatory Submission
biliary calculus, nos
persons
Data Change Date
Bile Duct Stone
People

---